Literature DB >> 31348046

Activated protein C in neuroprotection and malaria.

Laurent O Mosnier1.   

Abstract

PURPOSE OF REVIEW: Activated protein C (APC) is a homeostatic coagulation protease with anticoagulant and cytoprotective activities. Focusing on APC's effects in the brain, this review discusses three different scenarios that illustrate how APC functions are intimately affecting the physiology and pathophysiology of the brain. RECENT
FINDINGS: Cytoprotective APC therapy holds promise for the treatment of ischemic stroke, and a recently completed trial suggested that cytoprotective-selective 3K3A-APC reduced bleeding in ischemic stroke patients. In contrast, APC's anticoagulant activity contributes to brain bleeding as shown by the disproportional upregulation of APC generation in cerebral cavernous malformations lesions in mice. However, too little APC generation also contributes to maladies of the brain, such as in case of cerebral malaria where the binding of infected erythrocytes to the endothelial protein C receptor (EPCR) may interfere with the EPCR-dependent functions of the protein C pathway. Furthermore, discoveries of new activities of APC such as the inhibition of the NLRP3-mediated inflammasome and of new applications of APC therapy such as in Alzheimer's disease and graft-versus-host disease continue to advance our knowledge of this important proteolytic regulatory system.
SUMMARY: APC's many activities or lack thereof are intimately involved in multiple neuropathologies, providing abundant opportunities for translational research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31348046      PMCID: PMC7840173          DOI: 10.1097/MOH.0000000000000528

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  125 in total

Review 1.  Role of Krüppel-like transcription factors in endothelial biology.

Authors:  G Brandon Atkins; Mukesh K Jain
Journal:  Circ Res       Date:  2007-06-22       Impact factor: 17.367

2.  Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury.

Authors:  Eimear M Gleeson; María G Dichiara; Agustina Salicio; Louise M Quinn; Clive Drakeford; Shane E Russell; Patrick T Walsh; Josune Orbe; José Hermida; Owen P Smith; James S O'Donnell; Ramón Montes; Roger J S Preston
Journal:  Blood       Date:  2015-06-17       Impact factor: 22.113

3.  Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke.

Authors:  M Shibata; S R Kumar; A Amar; J A Fernandez; F Hofman; J H Griffin; B V Zlokovic
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

Review 4.  The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications.

Authors:  Silvio Danese; Stefania Vetrano; Li Zhang; Victoria A Poplis; Francis J Castellino
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

Review 5.  Molecular mechanisms of inflammasome signaling.

Authors:  Anukriti Mathur; Jenni A Hayward; Si Ming Man
Journal:  J Leukoc Biol       Date:  2017-12-29       Impact factor: 4.962

6.  Kruppel-like factor 2 protects against ischemic stroke by regulating endothelial blood brain barrier function.

Authors:  Hong Shi; Baiyang Sheng; Feng Zhang; Chunying Wu; Rongli Zhang; Junqing Zhu; Kui Xu; Youzhi Kuang; Stephen C Jameson; Zhiyong Lin; Yanming Wang; Jun Chen; Mukesh K Jain; G Brandon Atkins
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-18       Impact factor: 4.733

7.  Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier.

Authors:  Rashid Deane; Barbra LaRue; Abhay P Sagare; Francis J Castellino; Zhihui Zhong; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2008-10-08       Impact factor: 6.200

8.  Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.

Authors:  Hai Po H Liang; Edward J Kerschen; Sreemanti Basu; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Raffaella Toso; Alireza R Rezaie; José A Fernández; Rodney M Camire; Wolfram Ruf; John H Griffin; Hartmut Weiler
Journal:  Blood       Date:  2015-09-04       Impact factor: 22.113

9.  Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers.

Authors:  Patrick Lyden; Howard Levy; Sara Weymer; Kent Pryor; William Kramer; John H Griffin; Thomas P Davis; Berislav Zlokovic
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Authors:  Zinan Zhou; Alan T Tang; Weng-Yew Wong; Sharika Bamezai; Lauren M Goddard; Robert Shenkar; Su Zhou; Jisheng Yang; Alexander C Wright; Matthew Foley; J Simon C Arthur; Kevin J Whitehead; Issam A Awad; Dean Y Li; Xiangjian Zheng; Mark L Kahn
Journal:  Nature       Date:  2016-03-30       Impact factor: 49.962

View more
  1 in total

1.  An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice.

Authors:  Bilgimol Chumappumkal Joseph; Byron Y Miyazawa; Charles T Esmon; Mitchell J Cohen; Annette von Drygalski; Laurent O Mosnier
Journal:  Blood Adv       Date:  2022-02-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.